Announced
Synopsis
Mubadala, an investment company, and G42, an artificial intelligence firm, agreed to acquire Diaverum, a health care provider, from Bridgepoint, a private equity firm, for $2bn. “Diaverum is an exceptional company providing vital treatments that enable patients suffering from chronic kidney disease to live fulfilling lives. Its pioneering digital care offering fully aligns with M42’s focus on leveraging advanced technological solutions to deliver precise, personalized patient care,” Hasan Jasem Al Nowais, Mubadala Health Chief Executive Officer.
Principals
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.